FindTrial
Sign In

A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00346957
Enrollment
128
Registered
2006-07-04
Start date
1999-04-30
Completion date
2003-04-30
Last updated
2012-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMD

Brief summary

The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.

Interventions

DRUGAnecortave acetate 30 mg

0.5ml administered onto the sclera once every six months for 24 months

DRUGAnecortave Acetate 15 mg

0.5ml administered onto the sclera once every six months for 24 months

DRUGAnecortave Acetate 3 mg

0.5ml administered onto the sclera once every six months for 24 months

OTHERAnecortave Acetate Vehicle

0.5ml administered onto the sclera once every six months for 24 months

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ages 50 years and over * Other protocol-defined inclusion and

Exclusion criteria

may apply.

Design outcomes

Primary

MeasureTime frame
Mean change in logMAR visual acuity at 12 months from baseline.12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026